Classification of Cytochrome P450 Inhibitors with Respect to Binding Free Energy and pIC50 Using Common Molecular Descriptors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Chemical Information and Modeling

• Publication date

  2009-09-24

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1021/ci900247tPMID 19777996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Classification of drug molecules considering their IC50 values using mixed-integer linear programming based hyper-boxes method

  2008cited by this paper
• Generalized Proteochemometric Model of Multiple Cytochrome P450 Enzymes and Their Inhibitors

  2008cited by this paper
• Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.

  2008cited by this paper
• Combining Naive Bayes and Decision Tables

  2008cited by this paper
• Classification of 1,4-Dihydropyridine Calcium Channel Antagonists Using the Hyperbox Approach

  2007cited by this paper
• The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.

  2007cited by this paper
• IN SILICO PREDICTION OF DRUG BINDING TO CYP2D6: IDENTIFICATION OF A NEW METABOLITE OF METOCLOPRAMIDE

  2006cited by this paper
• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  2006cited by this paper
• Using Bagging classifier to predict protein domain structural class.

  2006cited by this paper
• Computational models for predicting interactions with cytochrome p450 enzyme.

  2006cited by this paper
• A mixed-integer programming approach to multi-class data classification problem

  2006cited by this paper
• IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER

  2006cited by this paper
• Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.

  2005cited by this paper
• Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.

  2005cited by this paper
• A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries.

  2005cited by this paper
• Programming with Python

  2005cited by this paper
• QSAR and classification study of 1,4-dihydropyridine calcium channel antagonists based on least squares support vector machines.

  2005cited by this paper
• Cytochrome P 450 17 Hydroxylase / 17 , 20 Lyase ( CYP 17 ) Function in Cholesterol Biosynthesis : Identification of Squalene Monooxygenase ( Epoxidase ) Activity Associated with CYP 17 in Leydig Cells

  2005cited by this paper
• Alternative QSAR models for selected estradiol and cytochrome P450 ligands: comparison between classical, spectroscopic, CoMFA and GRID/GOLPE methods

  2005cited by this paper
• Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells.

  2005cited by this paper
• A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.

  2005cited by this paper
• Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.

  2005cited by this paper
• Scalable molecular dynamics with NAMD

  2005cited by this paper
• Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

  2005cited by this paper
• Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines

  2005cited by this paper
• Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8

  2005cited by this paper
• Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors.

  2004cited by this paper
• Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.

  2004cited by this paper
• The Many Roles of Computation in Drug Discovery

  2004cited by this paper
• Docking and scoring in virtual screening for drug discovery: methods and applications

  2004cited by this paper
• Transgenic mouse models of human CYP3A4 gene regulation.

  2003cited by this paper
• Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.

  2003cited by this paper
• Transgenic Mouse Models of Human CYP 3 A 4 Gene Regulation

  2003cited by this paper
• In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.

  2003cited by this paper
• SWISS-MODEL: an automated protein homology-modeling server

  2003cited by this paper
• The Meaning of Molecular Connectivity: A Bimolecular Accessibility Model*

  2002cited by this paper
• Handbook of Molecular Descriptors

  2002cited by this paper
• In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.

  2001cited by this paper
• Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors

  2001cited by this paper
• PLS-regression: a basic tool of chemometrics

  2001cited by this paper
• Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.

  2001cited by this paper
• Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities.

  2001cited by this paper
• Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery

  2001cited by this paper
• In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions.

  2001cited by this paper
• Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.

  2000cited by this paper
• Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.

  2000cited by this paper
• Quantitative Structure-Activity Relationships (QSAR) Study of Flavonoid Derivatives for Inhibition of Cytochrome P450 1A2

  2000cited by this paper
• Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

  2000cited by this paper
• Special Invited Paper-Additive logistic regression: A statistical view of boosting

  2000cited by this paper
• Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450

  2000cited by this paper
• Unsupervised Forward Selection: A Method for Eliminating Redundant Variables

  2000cited by this paper
• In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines.

  1999cited by this paper
• Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.

  1999cited by this paper
• Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions.

  1999cited by this paper
• The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.

  1999cited by this paper
• Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.

  1999cited by this paper
• Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast

  1999cited by this paper
• Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations.

  1999cited by this paper
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.

  1998cited by this paper
• Inhibition and induction of human cytochrome P450 (CYP) enzymes.

  1998cited by this paper
• All-atom empirical potential for molecular modeling and dynamics studies of proteins.

  1998cited by this paper
• Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.

  1997cited by this paper
• Bayesian Network Classifiers

  1997cited by this paper
• QSAR and 3D QSAR in drug design Part 1: methodology

  1997cited by this paper
• Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.

  1996cited by this paper
• Topological indices and real number vertex invariants based on graph eigenvalues or eigenvectors

  1991cited by this paper
• An index of electrotopological state for atoms in molecules

  1991cited by this paper
• Networks for approximation and learning

  1990cited by this paper
• Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.

  1988cited by this paper
• Structural determination of paraffin boiling points.

  1947cited by this paper

• Leveraging-Induced Polarization for Drug Discovery: Efficient IC50 Prediction Using Minimal Features

  2025cites this paper
• Computational prediction of cytochrome P450 inhibition and induction.

  2019cites this paper
• Milp-hyperbox classification for structure-based drug design in the discovery of small molecule inhibitors of SIRTUIN6

  2016cites this paper
• Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.

  2015cites this paper
• QSAR and Molecular Modeling Approaches for Prediction of Drug Metabolism

  2015cites this paper
• Mass Spectrometry Based Identification of Geometric Isomers during Metabolic Stability Study of a New Cytotoxic Sulfonamide Derivatives Supported by Quantitative Structure-Retention Relationships

  2014cites this paper
• Evaluation of the HC-04 Cell Line as an In Vitro Model for Mechanistic Assessment of Changes in Hepatic Cytochrome P450 3A during Adenovirus Infection

  2014influential citation
• Combinations of fragment descriptors for improved prediction of CYP2C19 inhibitors

  2014cites this paper
• Microsoft Word-49791112-file00

  2014cites this paper
• DMD056663 1191..1201

  2014influential citation
• Machine learning for translational medicine

  2013cites this paper
• Structural and dynamic basis of human cytochrome P450 7B1: a survey of substrate selectivity and major active site access channels.

  2013cites this paper
• The challenges involved in modeling toxicity data in silico: a review.

  2012cites this paper
• QSAR Modelling of CYP3A4 Inhibition as a Screening Tool in the Context of DrugDrug Interaction Studies

  2012cites this paper
• Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme

  2012cites this paper
• Evaluation of pharmacological properties of Danshen compounds by computational and biochemical approaches

  2012cites this paper
• Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms

  2012cites this paper
• Structure Based Discovery of Small Molecules to Regulate the Activity of Human Insulin Degrading Enzyme

  2012cites this paper
• Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.

  2011cites this paper
• Optimization Based Tumor Classification from Microarray Gene Expression Data

  2011cites this paper
• Classification of Cytochrome P450 Inhibitors and Noninhibitors Using Combined Classifiers

  2011cites this paper
• Computational modeling of P450s for toxicity prediction

  2011influential citation
• A comparison of different QSAR approaches to modeling CYP450 1A2 inhibition

  2011cites this paper
• Advances in human cytochrome p450 and personalized medicine.

  2011cites this paper
• Pharmaceutical Perspectives of Nonlinear QSAR Strategies

  2010cites this paper